N-tert-Butyl-2,3-dihydro-1-benzofuran-5-amine | 61090-72-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: N-tert-Butyl-2,3-dihydro-1-benzofuran-5-amine
• CAS: 61090-72-0
• 化学式: C₁₂H₁₇NO
• 分子量: 191.27
• InChiKey: UMKXMLIYRHKQIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMPOUNDS FOR TREATING PULMONARY HYPERTENSION
  申请人：Klein Martina

  公开号：US20100113452A1

  公开（公告）日：2010-05-06

  The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

  本发明涉及用于治疗、预防或管理肺动脉高压的制药组合物和组合物，包括小分子杂环类药物，特别是取代的吡啶和吡啶二氮杂环，可选地与至少一种其他治疗剂联合使用。
• SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：Dumas Jacques P.

  公开号：US20110263597A1

  公开（公告）日：2011-10-27

  Methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using substituted pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R 1 and R 2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents.

  使用具有抑制血管生成活性的取代吡啶并噻唑化合物治疗具有异常血管生成或高通透性过程特征的哺乳动物的方法，其具有广义结构公式，其中包含A、B、D、E和L的环为苯或含氮杂环；X和Y基团可以是各种定义的连接单元之一；R1和R2可以是独立定义的取代基，也可以一起定义环的定义桥；环J可以是芳基、吡啶基或环烷基；G基团可以是任何定义的取代基。
• Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US10287255B2

  公开（公告）日：2019-05-14

  A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity, wherein X, Q, N, R1, R2, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.

  具有组蛋白去乙酰化酶 6 (HDAC6) 抑制活性的式 (I) 化合物、 其中X、Q、N、R1、R2、L和n如所述，其异构体或其药学上可接受的盐、其用于制备治疗药物的用途、包含其的药物组合物、使用该组合物治疗疾病的方法以及制备该新型化合物的方法。根据本发明的新型化合物具有组蛋白去乙酰化酶6（HDAC6）抑制活性，可有效预防或治疗HDAC6相关疾病，包括癌症、炎症性疾病、自身免疫性疾病、神经系统疾病和神经退行性疾病。
• NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US20170096405A1

  公开（公告）日：2017-04-06

  The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.
• PHARMACEUTICAL COMPOSITION COMPRISING HISTONE DEACETYLASE 6 INHIBITORS
  申请人：Chong Kun Dang Pharmaceutical Corp.

  公开号：US20220008414A1

  公开（公告）日：2022-01-13

  The present invention relates to a pharmaceutical composition for preventing or treating CMT disease, comprising histone deacetylase 6 inhibitor. The pharmaceutical composition according to the present invention has histone deacetylase 6 (HDAC6) inhibitory activity and thus is effective in preventing or treating CMT disease.